Search
Now showing items 1-6 of 6
Developing independent investigators for clinical research relevant for Africa
(BioMed Central, 2012)
Sustainable research capacity building requires training individuals at multiple levels within a supportive institutional infrastructure to develop a critical mass of independent researchers. At many African medical ...
Cognitive dysfunction among HIV positive and HIV negative patients with psychosis in Uganda
(Public Library of Science, 2012)
Background: Cognitive impairment is an established phenomenon in HIV infected individuals and patients that have
psychosis. However there is need to establish the severity of the impairment if patients are co morbid with ...
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
(Journal of Antimicrobial Chemotherapy, 2012-02-08)
Background: Treatment of HIV/malaria-coinfected patients with antiretroviral therapy (ART) and artemisininbased combination therapy has potential for drug interactions. We investigated the pharmacokinetics of artemether, ...
Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults
(BioMed Central, 2012-04-27)
Background: Severe malaria is a medical emergency with high mortality. Prompt achievement of therapeutic concentrations of highly effective anti-malarial drugs reduces the risk of death. The aim of this study was to assess ...
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
(Oxford University Press, 2012)
Objectives: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz ...
VS411 Reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics
(PLoS One, 2012)
Background: A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels ...